WeTrials
Recruiting

A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

What is this study?

This study is testing an experimental medication called ACT001 to see if it is safe and effective for children and young adults with certain types of aggressive brain tumors. Researchers hope this new treatment will help when standard therapies are not enough.

Who can participate?

This study is open to patients between 1 and 39 years old who have been diagnosed with specific types of brain tumors, such as DIPG. Participants must have recently finished their standard radiation treatment and meet specific timing requirements regarding past medications.

What will happen?

Participants will take the experimental medication ACT001 as part of the study treatment. Doctors will closely monitor their health and progress through regular check-ups and brain scans.

Where and when?

The study is currently recruiting patients at medical centers in Aurora, Colorado; Washington, D.C.; and Miami, Florida. Joining means visiting one of these participating locations for care.

Key Points
  • 1Tests the experimental medication ACT001 for specific brain tumors.
  • 2Open to patients aged 1 to 39 who have finished recent radiation therapy.
  • 3Currently recruiting at locations in Colorado, Washington D.C., and Florida.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPGRecurrent DIPGH3K27-altered High Grade Glioma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.